Literature DB >> 21060064

Third-generation SERMs may face uphill battle.

Charlie Schmidt.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 21060064     DOI： 10.1093/jnci/djq477

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  9 in total

1.  Perspective: The big C - for Chemoprevention.

Authors:  Michael B Sporn
Journal:  Nature       Date:  2011-03-24       Impact factor: 49.962

Review 2.  Bazedoxifene: a review of its use in the treatment of postmenopausal osteoporosis.

Authors:  Sean T Duggan; Kate McKeage
Journal:  Drugs       Date:  2011-11-12       Impact factor: 9.546

Review 3.  New directions for drug-resistant breast cancer: the CDK4/6 inhibitors.

Authors:  Mark Nichols
Journal:  Future Med Chem       Date:  2015-08-26       Impact factor: 3.808

4.  Osteoporosis: A Review of Treatment Options.

Authors:  Kristie N Tu; Janette D Lie; Chew King Victoria Wan; Madison Cameron; Alaina G Austel; Jenny K Nguyen; Kevin Van; Diana Hyun
Journal:  P T       Date:  2018-02

Review 5.  Development of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancer.

Authors:  Quan Jiang; Shilong Zheng; Guangdi Wang
Journal:  Future Med Chem       Date:  2013-06       Impact factor: 3.808

6.  A systematic in silico mining of the mechanistic implications and therapeutic potentials of estrogen receptor (ER)-α in breast cancer.

Authors:  Xin Li; Rong Sun; Wanpeng Chen; Bangmin Lu; Xiaoyu Li; Zijie Wang; Jinku Bao
Journal:  PLoS One       Date:  2014-03-10       Impact factor: 3.240

Review 7.  Soy and Health Update: Evaluation of the Clinical and Epidemiologic Literature.

Authors:  Mark Messina
Journal:  Nutrients       Date:  2016-11-24       Impact factor: 5.717

Review 8.  Molecular Mechanisms and Emerging Therapeutics for Osteoporosis.

Authors:  Ji-Yoon Noh; Young Yang; Haiyoung Jung
Journal:  Int J Mol Sci       Date:  2020-10-15       Impact factor: 5.923

9.  Cyclopia extracts act as ERα antagonists and ERβ agonists, in vitro and in vivo.

Authors:  Koch Visser; Morné Mortimer; Ann Louw
Journal:  PLoS One       Date:  2013-11-04       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.